Theravance Biopharma, Inc. — Earnings Quality Grade C
TBPH · Healthcare
Some red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO surged by 50 days (105 → 155)
Small-cap context: DSO swings on a small revenue base are more often quarterly customer-mix effects than red flags.
AR growth 147.0% exceeds revenue growth 66.9%
Revenue 66.9%, CFFO 2168.0%. Cash follows revenue
Expense Quality
No material inventory
CapEx growth -87.3% vs revenue 66.9%. Normal
Insufficient data
Insufficient data
Cash Flow Quality
CFFO/NI = 2.25. Profits backed by cash
FCF $0.2B, FCF/NI = 2.25
Accruals ratio = -27.3%. Low accruals
Cash $0.3B covers debt $0.0B
Balance Sheet Health
No goodwill. Clean balance sheet
Interest coverage = -1.5x (<2x). Financial stress
Other assets -83.7% vs revenue 66.9%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 2/3 years
No goodwill
Manipulation Score
Insufficient data
Portfolio monitoring
Monitor TBPH continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25